BioMed X Launches Drug Delivery Research Project with Janssen

News
Article

The project is aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.

BioMed X, a German independent research institute, announced on Jan. 26, 2021 that it is launching a research project with Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, aimed at discovering novel transport mechanisms in the human intestinal tract that could be used for oral delivery of diverse therapeutic modalities.

“There are several techniques available to shield these macromolecules from the harsh conditions of the gastrointestinal tract, but little progress has been made to translocate complex macromolecules across the intestinal epithelial barrier into systemic circulation,” said Christian Tidona, founder and managing director of the BioMed X Institute, in a company press release. “This project has the potential to provide us with a novel delivery platform that enables the development of a new generation of oral immunotherapies.”

The companies are currently searching for early-career biomedical researchers interested in the field of drug delivery to head the project and plan on hiring one group leader, two postdoctoral researchers, and two research assistants, BioMed X said in the press release.

Source: BioMed X

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content